Search
IR208
go.drugbank.com/drugs/DB05106InvestigationalIt contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial.
Biropepimut-S
go.drugbank.com/drugs/DB14816InvestigationalBiropepimut-S is under investigation in clinical trial NCT02873819 (Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral
N-Acetylmethionine
go.drugbank.com/drugs/DB01646InvestigationalSynonyms: Acetyl-L-methionine, L-(N-Acetyl)methionineMixtures: AZONEFROL-PD PERİTON DİYALİZ ÇÖZELTİSİ, 2000 ML TEKLİ TORBA, AZONEFROL-PD PERİTON DİYALİZ ÇÖZELTİSİ, 2500 ML ÇİFTLİ TORBAOctisalate
go.drugbank.com/drugs/DB11062ApprovedAlso known as Ethylhexyl Salicylate. Octyl salicylate is an oil soluble chemical sunscreen agent that absorbs UVB radiation. It does not protect against UVA. Octyl salicylate is used to augment the UVB protection in a sunscreen. Salicyla...
Mixtures: Anthelios XL Stick, Pl-18492-(5-fluoro-pentyl)-2-methyl-malonic-acid
go.drugbank.com/drugs/DB16029Investigational2-(5-fluoro-pentyl)-2-methyl-malonic-acid is under investigation in clinical trial NCT00696943 (18F ML-10 for Early Detection of Response of Brain Metastases to SRS).
Elsulfavirine
go.drugbank.com/drugs/DB14929InvestigationalElsulfavirine is under investigation in clinical trial NCT03706898 (Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food
XTL-001
go.drugbank.com/drugs/DB05405InvestigationalXTL001 is an investigational monoclonal antibody (MAb) product developed by XTL Biopharmaceuticals to evaluate the safety profile and antiviral activity of the compound in patients chronically infected
Subasumstat
go.drugbank.com/drugs/DB16406InvestigationalSubasumstat is under investigation in clinical trial NCT03648372 (A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced
AT9283
go.drugbank.com/drugs/DB05169InvestigationalAT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer. It was discovered and developed internally using Astex’s fragment-based drug discovery platform, Pyramid.
Synonyms: 1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-ureaAttapulgite
go.drugbank.com/drugs/DB01574ApprovedVet approvedWithdrawnAttapulgite is a magnesium aluminium phyllosilicate which occurs in a type of clay soil common to the Southeastern United States. When used in medicine, it physically binds to acids and toxic substances in the stomach and digestive tract...
Mixtures: Donnagel-PG CapProducts: DIASORB 100 ML SUSPANSIYON, DIYASORB 100 ML SUSPANSIYON